Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-mesothelin CAR T cells in Mesothelin Positive Tumors
NCT02930993Phase 1Unknown
- Sponsor
- Emergency General Hospital
- Start
- Aug 2016
- Primary completion
- Aug 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-meso cells in pancreatic adenocarcinoma (PDAC), ovarian cancer and pleural mesothelioma, sponsored by Emergency General Hospital. Primary endpoint: Incidents of treatment related adverse events at 2 years. Status: unknown.
02
Drugs
CART-meso cells
03
Conditions
pancreatic adenocarcinoma (PDAC)ovarian cancerpleural mesothelioma
Beyond the preview
Go deeper on NCT02930993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930993.